Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer's Core Leaders Outline Drive To Downsize In U.S., Europe While Expanding In BRIC Countries Including China

This article was originally published in PharmAsia News

Executive Summary

BEIJING - The core leaders of one of the globe's top pharmaceutical players - Pfizer Inc - told shareholders this week that they would push forward with a worldwide operation to reduce costs by downsizing in the West while ramping up sales forces in China and the other BRIC emerging markets

You may also be interested in...



Pfizer, Wyeth Japan Subsidiaries Merge To Become Second-largest Pharma

TOKYO - Pfizer Japan and Wyeth Japan, both of them fully owned by their U.S. parent firms, announced their merger, effective June 1, becoming Japan's second-largest pharmaceutical manufacturer after Takeda Pharmaceutical Co. and expanding Pfizer Japan's cardio and neural product lineup with Wyeth's vaccines

Pfizer, Wyeth Japan Subsidiaries Merge To Become Second-largest Pharma

TOKYO - Pfizer Japan and Wyeth Japan, both of them fully owned by their U.S. parent firms, announced their merger, effective June 1, becoming Japan's second-largest pharmaceutical manufacturer after Takeda Pharmaceutical Co. and expanding Pfizer Japan's cardio and neural product lineup with Wyeth's vaccines

In China, Promotion Trumps Patents

HONG KONG - In the late 1980s, Warner-Lambert researcher Bruce Roth came up with atorvastatin and changed the pharmaceutical market, and social and healthcare awareness factors in the West that made Lipitor the biggest blockbuster ever are starting to show up in China and other Asian countries. Cholesterol, heart attacks and the gamut of cardiovascular diseases are on the rise as diets grow richer, lifestyles more sedentary and smoking remains prevalent

Related Content

UsernamePublicRestriction

Register

SC027449

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel